News | June 29, 2020

Iterum Therapeutics Announces Topline Results from its Phase 3 Clinical Trial of Oral Sulopenem for the Treatment of Uncomplicated Urinary Tract Infections Sulopenem demonstrates superiority in treatment of patients with quinolone resistant pathogens Company to...

News | March 31, 2020

Iterum Therapeutics Provides Update on Phase 3 Clinical Trials of Sulopenem in Complicated Urinary Tract Infection (cUTI) and Uncomplicated Urinary Tract Infection (uUTI) Topline results from uUTI and cUTI clinical trials to be announced in Q2 2020 Iterum Therapeutics...

News | January 17, 2020

Iterum Therapeutics Announces $52 Million Private Placement with New and Existing Investors DUBLIN, Ireland and CHICAGO, Jan. 17, 2020 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on...